Fanni Natanegara, PhD, is currently the Group Leader for the Early Phase Statistics Neuroscience team at Eli Lilly and Company. She is responsible for the statistical strategy and deliverables of early phase portfolio in the Neurodegeneration and Pain therapeutic areas.
Dr. Natanegara joined Eli Lilly in June 2003 as a project statistician for the US Affiliate and commercialization effort. In 2006, she relocated to Singapore providing statistical leadership in the early phase development across multiple therapeutic areas at the Lilly-NUS Center for Clinical Pharmacology Unit. She returned to Indianapolis in 2008 to provide statistical leadership for the Diabetes early phase development and subsequently joined the Advanced Analytics Hub where she led tailored Bayesian trainings to US and outside of US colleagues, provided Bayesian consultations for asset teams, as well as developed tools, templates, guidance documents, and education materials. This effort has resulted in the broader use of Bayesian methods across portfolio at Lilly. In 2014, Dr. Natanegara served as the Group Leader for the Advanced Analytics Hub supporting neuroscience, cardiovascular and urology asset teams across the clinical phases of drug development. She later joined the Statistical Innovation Center and Neuroscience Design Hub and consulted with multiple early phase neuroscience clinical development programs while working to accelerate Eli Lilly’s clinical development transformation.
Dr. Natanegara is actively engaged in external professional organizations. She is the current Chair of the cross industry-regulatory-academic Drug Information Association (DIA) Bayesian Scientific Working Group with a vision to ensure that Bayesian methods are well-understood and broadly utilized for design and analysis throughout the medical product development process and to improve industrial, regulatory, and economic decision making. She is the Vice-Chair of the American Statistical Association (ASA) Statistical Partnership among Academe, Industry, and Government (SPAIG) committee with a charge to identify, lead, and promote initiatives that foster statistical partnerships or amongst Academic, Industry, and/or Government sectors. She also served on multiple working groups in the Pharmaceutical Research and Manufacturers of America (PhRMA) efforts to provide statistical influence on regulatory policy.
Dr. Natanegara received her doctorate in Statistics in 2003 from Baylor University, Waco, Texas. Her dissertation was titled “Bayesian Models for Circular Data”. She is also a co-author of the book “Bayesian Applications in Pharmaceutical Development”.